Butorphanol

CHEMBL33986 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

327.5 g/mol

LogP

3.8

Phase

4

A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.

Molekularmasse

327,5000 g/mol

LogP

3,80

TPSA

43,70 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pain Management Generalized Anxiety Disorder Chronic Pain

Wirkmechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3

InChI

InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1

Molecular Formula

C21H29NO2

HBD / HBA

2 / 3

Rotierbare Bindungen

2

Schwere Atome

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Butorphanol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL33986. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5361092. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Butorphanol auf PillFYI

Struktur

Schnelldaten

Formel: C21H29NO2
Synonyme: 5

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.